Treatment of Binge Eating Disorder in Comorbid Obesity
Binge eating disorder (BED) frequently co-occurs with obesity. When both conditions are present, treatment must address the eating disorder and excess body weight together, with clinical guidelines specifically recognising this combination as a distinct treatment scenario.
Clinical scenario
This protocol applies to patients diagnosed with binge eating disorder who also have comorbid obesity. Guidelines consistently support the use of antiobesity pharmacotherapy in this specific population, targeting both conditions concurrently.
Treatment approach
Management in this scenario centres on antiobesity medication — a pharmacological intervention class with evidence in patients with BED and comorbid obesity. The complete regimen, including specific agents and their indications, is available in the full protocol.
Clinical goals: Weight loss and reduction of binge eating.
References
- Consistently, two out of two guidelines reporting on antiobesity medications explicitly recommended their use, specifically orlistat, for weight loss in patients with BED and comorbid obesity.
- In addition to weight loss, the antiobesity medication sibutramine was recommended for reducing binge eating (the United States).
DOI: 10.1097/YCO.0000000000000360
View source ↗